Written and maintained by CASRAI Editorial Board
Last updated
This page is general information for researchers and lab and clinic staff, not medical advice and not a treatment guide.
Short answer
An oncolytic virus is a virus, naturally occurring or genetically engineered, that infects and lyses cancer cells. Its effect has two parts: direct killing of tumor cells and the induction of antitumor immunity. In the United States, one product is FDA-approved: talimogene laherparepvec (T-VEC, Imlygic), a modified herpes simplex virus type 1.
Definition and scope
A review in PMC (PMC8411207) describes oncolytic viruses (OVs) as viruses that “specifically infect and lyse cancer cells,” whether naturally occurring or engineered, and states that the therapeutic effect includes “direct oncolysis and the induction of antitumor immunity.” The therapy is also called oncolytic virotherapy or virotherapy. The term covers an agent that is meant to replicate selectively in tumor tissue; that distinguishes it from the non-replicating delivery vehicles discussed in our guide to viral vector types, which carry a therapeutic gene but are not themselves the active killing agent (an editorial distinction, drawn from how the two categories are used, not a regulatory definition).
How oncolytic viruses work
Direct oncolysis
The virus infects tumor cells and the infected cells lyse. The review notes that efficacy is not due only to this direct killing.
Antitumor immunity
Lysis releases tumor antigens. According to the same review, infection can recruit T cells and natural killer cells, support dendritic cell maturation and cross-presentation to CD8+ T cells, and shift a “cold” tumor microenvironment toward a “hot” one.
Arming and combination
Efficacy can be improved by “arming” the virus with immune-stimulating genes and by combining it with immune-checkpoint inhibitors. The review expects the two approaches to work synergistically: virotherapy raises T cell infiltration, and checkpoint inhibitors keep those T cells from becoming anergic.
Backbones and arming genes named in the literature
| Category | Examples named in the review |
|---|---|
| Herpes simplex virus backbones | HSV-1 and HSV-2 (including T-VEC) |
| Adenovirus backbones | Ad5-D24, ICOVIR-15K, enadenotucirev |
| Other virus backbones | Vaccinia, reovirus, vesicular stomatitis virus, Newcastle disease virus, measles virus, coxsackievirus B3, myxoma virus, Maraba virus |
| Cytokine arming genes | GM-CSF, IFN-β, IL-2, IL-12, IL-15, IL-10 |
| Chemokine arming genes | CCL5, CXCL9, CXCL10, CXCL11 |
| Costimulatory ligands | B7, GITRL, OX40L, 4-1BBL, CD40L |
| Checkpoint-related and other payloads | Anti-CTLA-4, soluble PD-1, HSP70, bispecific T cell engagers (BiTEs) |
Source for every row: PMC8411207 (read 2026-11-11). Inclusion in the table means the review names the example, not that the product is approved or in a particular trial phase.
T-VEC, the approved example
The review calls T-VEC “a first-in-class oncolytic virus based on modified herpes simplex virus type 1 (HSV-1)” and lists it as the one OV with FDA approval for clinical use. The FDA’s Imlygic page (read 2026-11-11) classifies it as a biologic under Gene Therapy products, lists BioVex Inc. (a wholly owned subsidiary of Amgen) as the manufacturer, gives the biologics license as STN 125518, and states the indication as local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. Reported combination results in the review include T-VEC plus ipilimumab (phase II, n=198; objective response rate 39% versus 18% for ipilimumab alone) and T-VEC plus pembrolizumab (phase 1b, n=21; 62%). Those are trial figures, not an indication.
Where it matters for labs and clinics
Because the product is a live, replication-competent virus, regulators ask a question that does not arise for most drugs: can it leave the patient and reach other people? FDA’s guidance “Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products” (final, August 2015; read 2026-11-11) defines shedding as release of the product from the patient through excreta, secreta (such as urine, saliva or nasopharyngeal fluids) or the skin (pustules, sores or wounds). It says shedding data help assess possible spread to untreated people, such as close contacts and health care professionals, and that shedding is distinct from biodistribution, which concerns spread within the body from the administration site.
Checklist of regulatory concepts
- Classification: T-VEC is regulated as a biologic and listed by FDA among gene therapy products.
- Shedding versus biodistribution: shedding is release from the patient; biodistribution is movement inside the body.
- Shedding studies are described for both preclinical and clinical development in the 2015 guidance.
- Development pathway: clinical use of an unapproved agent runs through an investigational new drug application, and expedited programs such as those compared in FDA expedited programs and accelerated approval may apply to qualifying products.
Handling, containment and biosafety classification of a specific product are set by its protocol, label and institutional oversight, not by this page.
Common misunderstandings
- “Oncolytic viruses only kill cells directly.” The literature credits the immune response as a major part of the effect.
- “Many oncolytic viruses are approved.” The review lists T-VEC as the one with FDA approval for clinical use; others named in the table are investigational examples.
- “It is the same as a gene therapy vector.” FDA groups T-VEC with gene therapy products, but the usual vector role (delivering a gene into cells) differs from an agent whose own replication and lysis are the therapy; see the editorial note above.
- “Shedding means the patient is dangerous.” Shedding is a measured property studied to assess possible spread; the guidance frames it as data for risk assessment.
FAQ
What is an oncolytic virus?
A naturally occurring or engineered virus that infects and lyses cancer cells and can also prompt an antitumor immune response.
Is there an FDA-approved oncolytic virus?
Yes: T-VEC (Imlygic), a modified herpes simplex virus type 1, for local treatment of certain melanoma lesions as described on the FDA’s product page.
What does “arming” mean?
Inserting immune-stimulating genes, such as GM-CSF or other cytokines, into the virus to strengthen antitumor immunity.
What is viral shedding in this context?
Release of the product from the patient via excreta, secreta or skin lesions, as defined in FDA’s 2015 shedding-study guidance.
Sources
- FDA, Imlygic: fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/imlygic (read 2026-11-11).
- FDA, Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products (August 2015): FDA guidance page (read 2026-11-11).
- Current strategies in engaging oncolytic viruses with antitumor immunity, PMC8411207: pmc.ncbi.nlm.nih.gov/articles/PMC8411207 (read 2026-11-11).
